318 Results

People

  1. Motzer
    Motzer
  2. Rosenberg
    Rosenberg
  3. Hellmann
    Hellmann
  4. Rudin
    Rudin
  5. Schoenfeld
    Schoenfeld
  6. Iyer
    Iyer
  7. Ladanyi
    Ladanyi
  8. Wolchok
    Wolchok
  9. O'Cearbhaill
    O'Cearbhaill
  10. Rizvi
    Rizvi

Groups

  1. Department of Medicine (217)
  2. Solid Tumor Oncology Division (188)
  3. GSK Faculty (66)
  4. Hematologic Malignancies, Division of (65)
  5. Genitourinary Oncology Service (60)
  6. Department of Pathology and Laboratory Medicine (59)
  7. Sloan Kettering Institute Postdocs (52)
  8. Surgery (49)
  9. Thoracic Oncology (46)
  10. Weinberg Fellows (41)
  1. "programmed death 1 ligand 1"
Formats
  1. Journal Article (231)
  2. Review (46)
  3. Editorial (21)
  4. Correspondence (6)
  5. Guidelines (6)
  6. Research Letter (6)
  7. Miscellaneous (2)
Groups
  1. Department of Medicine (217)
  2. Solid Tumor Oncology Division (188)
  3. GSK Faculty (66)
  4. Hematologic Malignancies, Division of (65)
  5. Genitourinary Oncology Service (60)
  6. Department of Pathology and Laboratory Medicine (59)

More Groups

People
  1. Robert Motzer (20)
  2. Jonathan Rosenberg (16)
  3. Jedd Wolchok (15)
  4. Matthew Hellmann (14)
  5. Adam Schoenfeld (10)
  6. Charles Rudin (10)

More People

Years
  1. 2025 (25)
  2. 2024 (53)
  3. 2023 (44)
  4. 2022 (49)
  5. 2021 (29)
  6. 2020 (43)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (19)
  2. Clinical Cancer Research (17)
  3. Annals of Oncology (15)
  4. Journal of Clinical Oncology (14)
  5. Journal of Thoracic Oncology (8)
  6. New England Journal of Medicine (8)

More Publications

Publishers
  1. Elsevier Inc. (44)
  2. Nature Publishing Group (26)
  3. American Association for Cancer Research (24)
  4. Biomed Central Ltd (21)
  5. Oxford University Press (18)
  6. Elsevier Science, Inc. (17)

More Publishers

Results (318)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes associated with pembrolizumab monotherapy among adults with diffuse malignant peritoneal mesothelioma
    Journal Article

    Marmarelis, M. E.; Wang, X.; Roshkovan, L.; Grady, C. B.; Miura, J. T.; Ginsberg, M. S.; Ciunci, C. A.; Egger, J.; Walker, S.; Cercek, A.; more...
    JAMA Network Open (2023)

    Fulltext@MSK | Save
  • Tumors of the digestive system: Comprehensive review of ancillary testing and biomarkers in the era of precision medicine
    Review

    Molnar, A.; Monroe, H.; Basri Aydin, H.; Arslan, M. E.; Lightle, A.; Lee, H.; El Jabbour, T.
    Current Oncology (2023)

    Fulltext@MSK | Save
  • Clear cell adenocarcinoma in situ as a potential precursor lesion for sporadic invasive endocervical clear cell adenocarcinoma
    Research Letter

    Stolnicu, S.; Zannoni, G. F.; Soslow, R. A.
    International Journal of Gynecological Pathology (2023)

    Fulltext@MSK | Save
  • Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: A pooled analysis
    Journal Article

    Borghaei, H.; Ciuleanu, T. E.; Lee, J. S.; Pluzanski, A.; Caro, R. B.; Gutierrez, M.; Ohe, Y.; Nishio, M.; Goldman, J.; Ready, N.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227
    Journal Article

    Brahmer, J. R.; Lee, J. S.; Ciuleanu, T. E.; Bernabe Caro, R.; Nishio, M.; Urban, L.; Audigier-Valette, C.; Lupinacci, L.; Sangha, R.; Pluzanski, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Five-year clinical outcomes after neoadjuvant nivolumab in resectable non-small cell lung cancer
    Journal Article

    Rosner, S.; Reuss, J. E.; Zahurak, M.; Zhang, J.; Zeng, Z.; Taube, J.; Anagnostou, V.; Smith, K. N.; Riemer, J.; Illei, P. B.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: A subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial
    Journal Article

    Tomita, Y.; Kobayashi, K.; Kimura, G.; Oya, M.; Uemura, H.; Nishiyama, H.; Galsky, M. D.; Nasroulah, F.; Collette, S.; Broughton, E.; more...
    Japanese Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Medullary carcinoma of the ampulla has distinct clinicopathologic characteristics including common association with microsatellite instability and PD-L1 expression
    Journal Article

    Xue, Y.; Balci, S.; Pehlivanoglu, B.; Muraki, T.; Memis, B.; Saka, B.; Kim, G.; Bandyopadhyay, S.; Knight, J.; El-Rayes, B.; more...
    Human Pathology (2023)

    Fulltext@MSK | Save
  • Systemic therapy in bladder preservation
    Review

    Girardi, D. M.; Ghatalia, P.; Singh, P.; Iyer, G.; Sridhar, S. S.; Apolo, A. B.
    Urologic Oncology: Seminars and Original Investigations (2023)

    Fulltext@MSK | Save
  • Breast cancer pathology in the era of genomics
    Review

    Wen, H. Y.; Collins, L. C.
    Hematology/Oncology Clinics of North America (2023)

    Fulltext@MSK | Save